Delayed Antiviral Treatment in Suspected Encephalitis: Order, Administration, and Proof of Causation

A delayed-treatment claim requires more than proof that a serious illness progressed. It must establish when a response was indicated, what response was actually delivered, and whether the difference contributed to permanent harm. In suspected viral encephalitis, that inquiry frequently turns on two separate intervals: the time to clinical suspicion and the time from decision to administration of empirical antiviral therapy.

Each interval has its own evidence, its own responsible actors, and its own causation question. Collapsing them obscures where an alleged delay actually occurred.

Suspicion, not confirmation, is the relevant trigger

The Infectious Diseases Society of America’s 2008 encephalitis guideline recommends initiating empirical acyclovir in patients with suspected encephalitis while diagnostic studies are pending. The guideline is a clinical recommendation of its era, not a legal finding, and the applicable standard of care must be established through qualified expert testimony addressing the medicine as it stood at the time of the care in question.

Its significance for the analysis is structural. Where the standard calls for treatment on suspicion, the review must examine when the available findings supported suspicion, not when diagnostic certainty was reached. A defense position that treatment became relevant only after confirmation requires its own expert foundation.

An order is not the same event as administration

A medication chronology should separate four events: the clinical decision, order entry, availability or dispensing, and actual administration. Each is documented in a different part of the record and may involve different clinicians and departments.

Relevant records typically include physician orders, nursing notes, the medication administration record, pharmacy verification and dispensing data, electronic audit trails, and any transfer documentation. Where an order was changed, held, unclear, unavailable, or not administered when expected, the explanation belongs in the analysis. A source that reports only the diagnosis or the time of an order cannot establish the full treatment interval.

The purpose is to determine what happened. A discrepancy between order and administration times is a question for investigation, not proof of wrongdoing.

Institutional responsibility must be tied to a specific failure

The order-to-administration interval often raises questions about how a care system operates: how urgent orders are communicated and verified, how responsibility passes between clinicians and shifts, and how administration of time-sensitive medication is confirmed.

In Pennsylvania, those questions may support a direct claim against the hospital under Thompson v. Nason Hospital, 527 Pa. 330, 591 A.2d 703 (1991), which recognizes nondelegable duties including oversight of patient care and the formulation and enforcement of adequate rules and policies. A corporate negligence claim requires proof that the hospital had actual or constructive knowledge of the defect and that the failure was a substantial factor in the harm. The firm’s analysis of corporate negligence and vicarious liability addresses the distinction.

A system flaw unrelated to the outcome does not complete the analysis. Neither does the assumption that every delay reflects institutional failure. The duty, departure, and causal contribution must be established for the particular claim.

Causation requires an account of what earlier treatment would have changed

Even where a delay is established, a separate question remains: how did it affect the injury? That requires expert explanation of the disease process, the stage reached during the alleged delay, and the effect timely treatment would probably have had.

Pennsylvania and New Jersey address this problem through an increased-risk framework. Under Hamil v. Bashline, 481 Pa. 256, 392 A.2d 1280 (1978), where expert evidence shows that negligent delay increased the risk of the harm that occurred, the jury may determine whether that increased risk was a substantial factor in causing it. New Jersey applies a comparable standard where negligence combines with a preexisting condition, under Scafidi v. Seiler, 119 N.J. 93 (1990). Neither framework dispenses with expert proof of the disease mechanism or with the plaintiff’s burden. Delaware’s treatment of these questions requires separate analysis.

The defense will typically contend that the injury was established before any reasonable response could have been made, that the causative organism or process would not have responded to the treatment in question, or that the outcome would have been the same. Each contention has to be met with evidence specific to the patient’s course. The severity of the eventual disability documents consequence; it does not identify the causal role of any earlier decision. The firm has addressed when diagnostic delay becomes permanent neurological damage in more detail.

Litigation readiness

Matters of this kind are defended on the medicine. A claim that cannot identify the point at which suspicion was warranted, the interval attributable to each part of the care system, and the expert basis for concluding that timely therapy would have altered the outcome will not withstand dispositive motion practice. Matters involving this pattern are often referred by other counsel once the infectious disease and neurological expert demands become apparent; they are evaluated under the same standards.

The framework described here guides review of a record. It does not replace one. A case-specific conclusion requires the complete clinical documentation and appropriate expert analysis within the firm’s medical malpractice practice.